Numerous studies have reported that interleukin-6 (IL-6)/janus kinase (JAK)/STAT3 pathway is aberrantly hyperactivated in many types of cancer, and such hyperactivation is generally associated with a poor clinical prognosis. The gene discussed is STAT3; the disease is cancer.